Finance & Capital Markets

41. True DEI Value in Biopharma with Arcellx's Rami Elghandour 6/16/2024

    Asked about his company’s rapid rise since taking the helm in 2021, Arcellx CEO Rami Elghandour cites a few critical and risky decisions, the execution of some specific people on his all-star team, and a relentless commitment to diversity, equity, and inclusion. Before you skepticize, let me assure you: the man brings receipts.

42. Financing Biopharma Innovation With Allan Shaw 12/19/2022

    Friend and frequent guest Allan Shaw rejoins the Business of Biotech to reflect on his recent presentation on innovative biotech financing at the BioFuture event in NYC. We also dig into Bruce Booth's "Atlas Venture Year In Review," revisiting and unpacking some quoteworthy material and metrics from both sources. Allan offers up plenty of prognostication and professional insight in a preview of what's to come in 2023, complete with his signature "Allanisms" and colorful analogies. A can't-miss episode as we round the turn to a new year!

43. Biotech Dealmaking with Regeneron's Nouhad Husseini 11/22/2023

    When it comes to landing and executing strategic partnerships, Regeneron puts on a clinic. Partnerships, acquisitions, licensing agreements, and other deals large and small with Intellia, Decibel Therapeutics, BARDA, Alnylam, and Sonoma Therapeutics are just a sampling of those making news this year alone. The man behind much of that dealmaking is none other than Nouhad Husseini, SVP and Head of Business Development and Corporate Strategy at Regeneron.

44. Episode 4: Building Your Pitch With Leslie Williams 8/13/2020

    Leslie Williams is a multi-time biotech founder and board member who's honed her pitch-building skills to a fine point. On this episode of The Business Of Biotech, Williams shares best practices for building your pitch deck, how to draw out the nuance that makes your story unique, what to expect in your initial pitch session and follow-on meetings, and why the human element trumps everything else in an otherwise formulaic pitch process.

45. The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D. 3/4/2024

    In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity breeds skepticism from the investment community. Brian Finrow, J.D. embraces that reality and the challenges that come with it.

46. Risk Mitigation With MeiraGTx's Zandy Forbes, Ph.D. 12/30/2024

    Zandy Forbes, Ph.D., combines science and finance expertise to manage biotech risk. With a Ph.D. from Oxford, a postdoc fellowship, and over a decade as a Wall Street healthcare investor, she now leads Meira GTx as President & CEO. On Business of Biotech, she discusses how her investment experience informs her approach to biotech leadership.

47. BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience 1/29/2025

    From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way.

48. Episode 5: Finding Funding In Volatile Times With Ben Zeskind 8/13/2020

    Ben Zeskind launched his biotech, Immuneering, in the throes of the Great Recession. The company earned a $20 million series A round to fund the development of its pipeline at the outset of the COVID-19 pandemic. Along the way, it bootstrapped its way from bioinformatics company to fledgling biopharma. On this episode of The Business Of Biotech, Zeskind shares his experience-based wisdom on finding funding in volatile times.

49. A Royalty Model For Value Creation With Zymeworks' Kenneth Galbraith 1/8/2026

    On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK.

50. Biotech M&A Anomalies With Allan Shaw 8/22/2022

    While many clinical-stage biopharmas are contracting or holding the line through the current market slump, Portage Biotech leaders Ian Walters, Allan Shaw, and company are making moves. The company recently acquired Tarus Therapeutics and iOx Therapeutics Ltd., extending its pipeline and positioning itself to meet some aggressive investor expectations. On this episode of the Business of Biotech, Shaw dissects the deals, digging into the M&A strategy at Portage and offering advice from the batter's box to leaders of early-stage biotechs.